Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2014

Liu S, Soong Y, Seshan SV, Szeto HH. Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation, and fibrosis. Am J Physiol Renal Physiol. 2014;306(9):F970-80.

Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014;20(11):2846-50.

Mancuso M, Cesarman E, Erickson D. Detection of Kaposi's sarcoma associated herpesvirus nucleic acids using a smartphone accessory. Lab Chip. 2014;14(19):3809-16.

Selvarajah S, Pyne S, Chen E, Sompallae R, Ligon AH, Nielsen GP, et al. High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin Cancer Res. 2014;20(6):1521-30.

Dim DC, Jiang F, Qiu Q, Li T, Darwin P, Rodgers WH, et al. The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration. Diagn Cytopathol. 2014;42(3):193-9.

Yigit N, Geyer JT. Bone marrow metastasis of prostatic adenocarcinoma with post-treatment foamy-like changes: A diagnostic pitfall. Can Urol Assoc J. 2014;8(11-12):E941-3.

Yue F, Cheng Y, Breschi A, Vierstra J, Wu W, Ryba T, et al. A comparative encyclopedia of DNA elements in the mouse genome. Nature. 2014;515(7527):355-64.

Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun. 2014;5:5383.

Huland DM, Jain M, Ouzounov DG, Robinson BD, Harya DS, Shevchuk MM, et al. Multiphoton gradient index endoscopy for evaluation of diseased human prostatic tissue ex vivo. J Biomed Opt. 2014;19(11):116011.

Taplin M-, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32(33):3705-15.